Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 17 May 2021 |
| Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons | 12 May 2021 |
| Genmab A/S has published its Articles of Association | 12 May 2021 |
| Capital Increase in Genmab as a Result of Employee Warrant Exercise | 11 May 2021 |
| Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons | 11 May 2021 |
| Transactions in connection with share buy-back program | 10 May 2021 |
| Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons | 7 May 2021 |